NCT01471041

Brief Summary

The SAVE Study will evaluate the safety and efficacy of the Venous Window Needle Guide in achieving access of a deep, un-cannulatable arteriovenous fistula to complete hemodialysis as prescribed.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
54

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Dec 2011

Shorter than P25 for phase_2

Geographic Reach
1 country

2 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 1, 2011

Completed
10 days until next milestone

First Posted

Study publicly available on registry

November 11, 2011

Completed
20 days until next milestone

Study Start

First participant enrolled

December 1, 2011

Completed
1.2 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2013

Completed
3 months until next milestone

Study Completion

Last participant's last visit for all outcomes

June 1, 2013

Completed
3 years until next milestone

Results Posted

Study results publicly available

June 3, 2016

Completed
Last Updated

June 3, 2016

Status Verified

April 1, 2016

Enrollment Period

1.2 years

First QC Date

November 1, 2011

Results QC Date

April 26, 2016

Last Update Submit

April 26, 2016

Conditions

Keywords

End Stage Renal DiseaseHemodialysisAV fistulaKidney failure

Outcome Measures

Primary Outcomes (1)

  • Use of Venous Window Needle Guide to Obtain Arteriovenous Access for Hemodialysis

    Successful cannulation of arteriovenous fistula through the VWNG device and successful hemodialysis achieved within 3 months from index procedure.

    3 months

Secondary Outcomes (1)

  • Arteriovenous Fistula Cannulation Complications While Using the Venous Window Needle Guide

    6 months

Study Arms (1)

Venous Window Needle Guide

EXPERIMENTAL

Venous Window Needle Guide will be implanted onto deep, un-cannulatable arteriovenous fistula

Device: Venous Window Needle Guide

Interventions

Subcutaneous, extravascular needle guide made of medical-grade titanium

Also known as: VWNG
Venous Window Needle Guide

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Deep, uncannulatable, upper extremity arteriovenous fistula
  • Minimum arteriovenous fistula flow 400 ml/min
  • One year life expectancy

You may not qualify if:

  • Non-transposed basilic or brachial vein arteriovenous fistula
  • History of peripheral vascular disease
  • History of cardiovascular disease
  • History of cerebral vascular disease

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Ladenheim Dialysis Access Centers

Fresno, California, 93710, United States

Location

University of Oklahoma - Tulsa

Tulsa, Oklahoma, 74104, United States

Location

Related Publications (1)

  • Jennings WC, Galt SW, Shenoy S, Wang S, Ladenheim ED, Glickman MH, Kathuria P, Browne BJ. The Venous Window Needle Guide, a hemodialysis cannulation device for salvage of uncannulatable arteriovenous fistulas. J Vasc Surg. 2014 Oct;60(4):1024-32. doi: 10.1016/j.jvs.2014.04.016. Epub 2014 May 13.

MeSH Terms

Conditions

Kidney Failure, ChronicArteriovenous FistulaRenal Insufficiency

Condition Hierarchy (Ancestors)

Renal Insufficiency, ChronicKidney DiseasesUrologic DiseasesFemale Urogenital DiseasesFemale Urogenital Diseases and Pregnancy ComplicationsUrogenital DiseasesMale Urogenital DiseasesChronic DiseaseDisease AttributesPathologic ProcessesPathological Conditions, Signs and SymptomsArteriovenous MalformationsVascular MalformationsCardiovascular AbnormalitiesCardiovascular DiseasesVascular FistulaVascular DiseasesCongenital AbnormalitiesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesFistulaPathological Conditions, Anatomical

Results Point of Contact

Title
Mark Crawford
Organization
Vital Access

Study Officials

  • Mark Crawford, BA

    Vital Access

    STUDY DIRECTOR

Publication Agreements

PI is Sponsor Employee
No
Restrictive Agreement
No

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
NONE
Purpose
TREATMENT
Intervention Model
SINGLE GROUP
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 1, 2011

First Posted

November 11, 2011

Study Start

December 1, 2011

Primary Completion

March 1, 2013

Study Completion

June 1, 2013

Last Updated

June 3, 2016

Results First Posted

June 3, 2016

Record last verified: 2016-04

Locations